These are valid concerns about the company.It's also valid...

These are valid concerns about the company.

It's also valid to hold onto hope that Novartis will pull through and fund another trial, or that they will find another partner, or the FDA challenge will succeed and they'll get to sell Remestemcell in the states.

There's a number of aces up their sleeve.

I do think them pulling a few of those aces out is already baked into the price at the moment though.

There is definitely potential in the products, they just need to figure out what the potential is and prove it through trials.

Phase 3 failed primary endpoints will not pique the FDAs interest. Not at all.

The secondary endpoints may get partners on board. But in the way that they'll fund trials for a piece of the pie. And unfortunately the ball is currently in the court of the partners, MSB doesn't seem to have a lot of bargaining power at this stage.

If Novartis pulls, and waits a quarter, if no one else steps up Novartis will be able to drive a much harder bargain as MSB burns through cash. They've only got 2.7 quarters (unless Si cuts his salary )

It'll be interesting to see how it plays out!

Purely IMO. DYOR. YOLO